vs

Side-by-side financial comparison of Avantor, Inc. (AVTR) and Tapestry, Inc. (TPR). Click either name above to swap in a different company.

Tapestry, Inc. is the larger business by last-quarter revenue ($2.5B vs $1.7B, roughly 1.5× Avantor, Inc.). Tapestry, Inc. runs the higher net margin — 22.4% vs 3.1%, a 19.3% gap on every dollar of revenue. On growth, Tapestry, Inc. posted the faster year-over-year revenue change (14.0% vs -1.4%). Tapestry, Inc. produced more free cash flow last quarter ($1.0B vs $117.2M). Over the past eight quarters, Tapestry, Inc.'s revenue compounded faster (29.9% CAGR vs -0.5%).

Avantor, Inc. is an American biotechnology, chemicals, and pharmaceutical company headquartered in Radnor, Pennsylvania. Established in 1904 as J.T. Baker, the company changed its name to Avantor in 2010. Avantor went public in 2019 and is now listed on the New York Stock Exchange under the symbol “AVTR”.

Tapestry, Inc. is a leading American multinational luxury fashion holding company. It owns three iconic lifestyle brands: Coach, Kate Spade New York, and Stuart Weitzman, offering premium handbags, apparel, footwear, accessories, and fragrances to global consumers via physical retail stores and e-commerce platforms.

AVTR vs TPR — Head-to-Head

Bigger by revenue
TPR
TPR
1.5× larger
TPR
$2.5B
$1.7B
AVTR
Growing faster (revenue YoY)
TPR
TPR
+15.3% gap
TPR
14.0%
-1.4%
AVTR
Higher net margin
TPR
TPR
19.3% more per $
TPR
22.4%
3.1%
AVTR
More free cash flow
TPR
TPR
$920.3M more FCF
TPR
$1.0B
$117.2M
AVTR
Faster 2-yr revenue CAGR
TPR
TPR
Annualised
TPR
29.9%
-0.5%
AVTR

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
AVTR
AVTR
TPR
TPR
Revenue
$1.7B
$2.5B
Net Profit
$52.4M
$561.3M
Gross Margin
31.5%
75.5%
Operating Margin
7.6%
28.6%
Net Margin
3.1%
22.4%
Revenue YoY
-1.4%
14.0%
Net Profit YoY
-89.5%
80.8%
EPS (diluted)
$0.08
$2.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVTR
AVTR
TPR
TPR
Q4 25
$1.7B
$2.5B
Q3 25
$1.6B
$1.7B
Q2 25
$1.7B
$1.7B
Q1 25
$1.6B
$1.6B
Q4 24
$1.7B
$2.2B
Q3 24
$1.7B
$1.5B
Q2 24
$1.7B
$1.6B
Q1 24
$1.7B
$1.5B
Net Profit
AVTR
AVTR
TPR
TPR
Q4 25
$52.4M
$561.3M
Q3 25
$-711.8M
$274.8M
Q2 25
$64.7M
$-517.1M
Q1 25
$64.5M
$203.3M
Q4 24
$500.4M
$310.4M
Q3 24
$57.8M
$186.6M
Q2 24
$92.9M
$159.3M
Q1 24
$60.4M
$139.4M
Gross Margin
AVTR
AVTR
TPR
TPR
Q4 25
31.5%
75.5%
Q3 25
32.4%
76.3%
Q2 25
32.9%
76.3%
Q1 25
33.8%
76.1%
Q4 24
33.4%
74.4%
Q3 24
32.9%
75.3%
Q2 24
34.1%
74.9%
Q1 24
34.0%
74.7%
Operating Margin
AVTR
AVTR
TPR
TPR
Q4 25
7.6%
28.6%
Q3 25
-40.0%
19.3%
Q2 25
7.7%
-33.9%
Q1 25
9.3%
16.0%
Q4 24
37.8%
22.4%
Q3 24
7.3%
16.7%
Q2 24
10.3%
14.8%
Q1 24
8.7%
13.8%
Net Margin
AVTR
AVTR
TPR
TPR
Q4 25
3.1%
22.4%
Q3 25
-43.8%
16.1%
Q2 25
3.8%
-30.0%
Q1 25
4.1%
12.8%
Q4 24
29.7%
14.1%
Q3 24
3.4%
12.4%
Q2 24
5.5%
10.0%
Q1 24
3.6%
9.4%
EPS (diluted)
AVTR
AVTR
TPR
TPR
Q4 25
$0.08
$2.68
Q3 25
$-1.04
$1.28
Q2 25
$0.09
$-2.30
Q1 25
$0.09
$0.95
Q4 24
$0.73
$1.38
Q3 24
$0.08
$0.79
Q2 24
$0.14
$0.67
Q1 24
$0.09
$0.60

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVTR
AVTR
TPR
TPR
Cash + ST InvestmentsLiquidity on hand
$365.4M
$1.1B
Total DebtLower is stronger
$3.9B
$2.4B
Stockholders' EquityBook value
$5.6B
$551.2M
Total Assets
$11.8B
$6.5B
Debt / EquityLower = less leverage
0.71×
4.32×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVTR
AVTR
TPR
TPR
Q4 25
$365.4M
$1.1B
Q3 25
$251.9M
$743.2M
Q2 25
$449.4M
$1.1B
Q1 25
$315.7M
$1.1B
Q4 24
$261.9M
$1.0B
Q3 24
$285.3M
$7.3B
Q2 24
$272.6M
$7.2B
Q1 24
$234.9M
$7.4B
Total Debt
AVTR
AVTR
TPR
TPR
Q4 25
$3.9B
$2.4B
Q3 25
$3.9B
$2.4B
Q2 25
$4.2B
$2.4B
Q1 25
$4.1B
$2.4B
Q4 24
$4.1B
$2.4B
Q3 24
$4.9B
$7.0B
Q2 24
$5.1B
$6.9B
Q1 24
$5.3B
$7.7B
Stockholders' Equity
AVTR
AVTR
TPR
TPR
Q4 25
$5.6B
$551.2M
Q3 25
$5.6B
$399.5M
Q2 25
$6.3B
$857.8M
Q1 25
$6.1B
$1.5B
Q4 24
$6.0B
$1.3B
Q3 24
$5.6B
$3.0B
Q2 24
$5.4B
$2.9B
Q1 24
$5.3B
$2.8B
Total Assets
AVTR
AVTR
TPR
TPR
Q4 25
$11.8B
$6.5B
Q3 25
$11.7B
$6.4B
Q2 25
$12.8B
$6.6B
Q1 25
$12.3B
$7.3B
Q4 24
$12.1B
$7.3B
Q3 24
$12.8B
$13.7B
Q2 24
$12.7B
$13.4B
Q1 24
$12.8B
$13.7B
Debt / Equity
AVTR
AVTR
TPR
TPR
Q4 25
0.71×
4.32×
Q3 25
0.69×
5.95×
Q2 25
0.67×
2.77×
Q1 25
0.67×
1.59×
Q4 24
0.68×
1.78×
Q3 24
0.89×
2.35×
Q2 24
0.94×
2.39×
Q1 24
1.00×
2.77×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVTR
AVTR
TPR
TPR
Operating Cash FlowLast quarter
$152.7M
$1.1B
Free Cash FlowOCF − Capex
$117.2M
$1.0B
FCF MarginFCF / Revenue
7.0%
41.5%
Capex IntensityCapex / Revenue
2.1%
1.7%
Cash ConversionOCF / Net Profit
2.91×
1.93×
TTM Free Cash FlowTrailing 4 quarters
$495.0M
$1.6B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVTR
AVTR
TPR
TPR
Q4 25
$152.7M
$1.1B
Q3 25
$207.4M
$112.6M
Q2 25
$154.4M
$446.8M
Q1 25
$109.3M
$144.3M
Q4 24
$173.3M
$506.0M
Q3 24
$244.8M
$119.5M
Q2 24
$281.1M
$256.0M
Q1 24
$141.6M
$97.8M
Free Cash Flow
AVTR
AVTR
TPR
TPR
Q4 25
$117.2M
$1.0B
Q3 25
$171.7M
$80.2M
Q2 25
$124.8M
$411.5M
Q1 25
$81.3M
$113.4M
Q4 24
$145.8M
$475.1M
Q3 24
$204.0M
$93.9M
Q2 24
$235.3M
$209.8M
Q1 24
$106.9M
$78.8M
FCF Margin
AVTR
AVTR
TPR
TPR
Q4 25
7.0%
41.5%
Q3 25
10.6%
4.7%
Q2 25
7.4%
23.9%
Q1 25
5.1%
7.2%
Q4 24
8.6%
21.6%
Q3 24
11.9%
6.2%
Q2 24
13.8%
13.2%
Q1 24
6.4%
5.3%
Capex Intensity
AVTR
AVTR
TPR
TPR
Q4 25
2.1%
1.7%
Q3 25
2.2%
1.9%
Q2 25
1.8%
2.0%
Q1 25
1.8%
2.0%
Q4 24
1.6%
1.4%
Q3 24
2.4%
1.7%
Q2 24
2.7%
2.9%
Q1 24
2.1%
1.3%
Cash Conversion
AVTR
AVTR
TPR
TPR
Q4 25
2.91×
1.93×
Q3 25
0.41×
Q2 25
2.39×
Q1 25
1.69×
0.71×
Q4 24
0.35×
1.63×
Q3 24
4.24×
0.64×
Q2 24
3.03×
1.61×
Q1 24
2.34×
0.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AVTR
AVTR

Laboratory Solutions Segment$1.1B67%
Bioscience Production Segment$547.5M33%

TPR
TPR

Coach$1.4B57%
Other$787.0M31%
Kate Spade Company$290.0M12%

Related Comparisons